Based on Clemson University research, 3D cancer cell modelling spinout Kiyatec has increased its total financing to $14.9m with the help of clinical lab operator LabCorp and VC firm VentureSouth.

Kiyatec, a US-based cancer cytology modelling spinout of Clemson University, obtained an initial $3m in series B2 funding on Wednesday led by VC firm VentureSouth and backed by clinical laboratory operator LabCorp.
Founded in 2005, Kiyatec has developed a technology called 3D-Predict that provides ex vivo predictive modelling of live cancer cells in 3D cell culture environments.
Kiyatec’s platform helps inform patient-specific clinical decisions when prescribing cancer therapies and also supports the development of new drugs.
The…